Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

Core Viewpoint - Altamira Therapeutics Ltd. has announced a public offering of common shares and warrants, aiming to raise approximately $4 million upfront, with potential additional proceeds of up to $8 million from the exercise of warrants [1][3]. Group 1: Offering Details - The public offering includes 5,555,556 common shares priced at $0.72 each, along with Series A-1 and Series A-2 common warrants, each allowing the purchase of an equal number of shares at the same price [1]. - The Series A-1 warrants will expire either 18 months after issuance or 60 days after positive biodistribution data is announced for AM-401 or AM-411 [1]. - The Series A-2 warrants will expire either five years after issuance or six months after entering agreements for further development and commercialization of AM-401 or AM-411 [1]. Group 2: Financial Proceeds and Use - The expected gross proceeds from the offering are approximately $4 million before fees and expenses, with an additional potential $8 million if all warrants are exercised [3]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 3: Company Background - Altamira Therapeutics is focused on developing RNA delivery technology for targets beyond the liver, with two flagship siRNA programs, AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis, currently in preclinical development [7]. - The company also holds a 49% stake in Altamira Medica AG, which markets Bentrio®, an OTC nasal spray for allergic rhinitis [8]. - Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with operations in Basel, Switzerland [8].